Novo Nordisk CEO Favors Trump Plan to Limit Rebates

Novo Nordisk's CEO discusses the company's optimistic growth outlook despite US pricing pressures. The conversation covers the impact of US rebate policy changes, international growth, and insulin pricing. The CEO highlights efforts to improve patient access and affordability, especially in the US, while addressing concerns about rising insulin prices.

What regions outside of the US does Nordisk see strong growth coming from?

What initiatives has Nordisk taken to help Americans who cannot afford their medicines?